学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
Menu
报名参会

已确认嘉宾Normal Guest

胡适 讲师

第二军医大学基础医学部

胡适 讲师

胡适,肿瘤学博士,第二军医大学基础医学部讲师。从事抗肿瘤生物技术药物的发现、作用机制及新靶标研究。以在包括Science Translation MedicineCancer ResearchJournal of Biological Chemistry等国际期刊上发表论著10余篇。主要学术成就包括原创性的设计开发制备四功能高价态抗体药物(Four-in-one technology)及肿瘤干细胞/肿瘤实体细胞双靶向抗体药物

 

代表论著

(1) Shi Hu*, Wenyan Fu, Tian Li, Ying Tang, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Yongji Yang, and Changhai Lei*. Antagonism of EGFR and Notch Limits Acquired Resistance to EGFR Inhibitors and Radiation by Decreasing Tumor-Initiating Cell Frequency. Science Translation Medicine, 2017. 9(380): p. eaag0339.

(2) Shi Hu*, Wenyan Fu, Weihao Xu, Yang Yang, Melissa Cruz, Sandra D Berezov, Daniel Jorissen, Hiroaki Takeda, and Wangdong Zhu*, Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer research, 2015. 75(1): p. 159-170.

(3) Shi Hu*, Haibin Dai, Tian Li, Ying Tang, Wenyan Fu, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Min Ding, Yongji Yang, and Changhai Lei*. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382(1): 32-43.

(4) Shi Hu, Shuaiyi Liang, Huaizu Guo, Dapeng Zhang, Hui Li, Xiaoze Wang, Weili Yang, Weizhu Qian, Sheng Hou, Hao Wang, Yajun Guo*, and Zhiyong Lou*, Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry, 2013. 288(38): p. 27059-27067.


邀请函

下载邀请函

赞助企业

大会咨询
姓名 *

E-mail*

电话: *

消息: *

×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: